logo
logo

Neomorph, Inc. Announces $109 Million Series A Financing to Advance Proprietary Protein Degradation Platform and Programs

Dec 22, 2020over 4 years ago

Amount Raised

$109 Million

Round Type

series a

San Diego

Description

Neomorph, Inc. announced a $109 million Series A financing to advance a proprietary targeted protein degradation platform and specific programs. Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD.

Company Information

Company

Neomorph, Inc

Location

San Diego, California, United States

About

A venture-backed biotechnology company based in San Diego, California, Neomorph is building a leading protein degradation entity, focused on “molecular glue” degraders. Neomorph’s mission is to use this technology to solve critical problems in human health with the discovery and development of innovative new medicines against “undruggable targets.”

Funding Insights

Based on industry data
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Related People